ATLANTA, June 5 (Reuters) - Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc., whose kidney cancer drug Nexavar was approved last December after it proved to slow tumor growth, said on Monday that the drug failed to significantly increase survival in a late stage trial.
